Study of infigratinib for children under 3 with achondroplasia
Part of Bones, joints & muscles, Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This trial tests an oral medication called infigratinib to see if it can help young children with achondroplasia. It is for children under 3 years old who have a confirmed genetic diagnosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must have achondroplasia confirmed by genetic testing (a lab report showing the specific gene change).
- Age must be between 0 and 32 months (under 2 years and 8 months) at the time of screening.
- Parents or guardians must agree to attend all study visits and follow the study instructions.
- Child must be able to swallow age-appropriate oral medication.
- Must not have had any other growth treatment for achondroplasia or short stature before or during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well infigratinib works and remains safe for children with achondroplasia. It includes children who already took infigratinib in a prior QED study, and some who are starting treatment for the first time.
This trial tests a new medicine, BMN 333, against an existing one (vosoritide) to see if it helps children with achondroplasia grow. It's for kids who haven't used these treatments before.
This trial tests a new medicine for children with achondroplasia (a common form of dwarfism). It aims to see if the drug can improve growth. The study is for children aged 2.5 to under 11 years old who have not started puberty and can walk without help.
This trial tests a new medicine (ABSK061) for children with achondroplasia, a common form of dwarfism. It aims to see if the drug is safe and can help with growth. Children age 3 to under 12 may qualify.
This trial tests a new weekly injection called TransCon CNP for infants with achondroplasia (the most common form of dwarfism). The goal is to see if it can help children grow better than a placebo (a shot with no medicine).
This trial tests a weekly injection called navepegritide for adolescents aged 12-18 with achondroplasia (a common form of dwarfism). The goal is to see if it can safely improve growth. You must have a genetic confirmation of achondroplasia and a historical height measurement from the past 6 to 15 months.
Hear when a new Achondroplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.